A RhoVac article is published in the June edition of MedNous, a publication of Evernow Publishing Ltd

RhoVac AB (”RhoVac”)  is published in the June edition of MedNous, through a written commentary by CEO Anders Månsson.

In order to further attract the attention of potential partners and increase their interest in RhoVac’s achievements as well as plans for the future, RhoVac’s CEO Anders Månsson has written a commentary on the company in the latest edition of MedNous that was published last week.  

CEO Anders Månsson comments: “It is important that we communicate on RhoVac more broadly than what can be accomplished in direct bi-lateral meetings, whether physical or digital. By reaching out also via the international press, informing on our achievements and our plans, we can also reach a broader audience and that is important from a business perspective.”

Link to the commentary on RhoVac in MedNous:https://www.rhovac.com/investors/presentations/

For further information, please contact:

Anders Månsson – CEO, RhoVac AB

Phone number: +46 73-751 72 78

E-mail: info@rhovac.com

About RhoVac AB

RhoVac® was established as a private company in Denmark in 2007. Under this company, the basic development steps for the drug candidate RV001 were undertaken. In 2015 the Swedish RhoVac AB was formed, which is now headquartered and in 2016 the company was listed on the then Aktietorget in Sweden (now Spotlight Stock Market). RhoVac® has now passed the early stages of development. In 2018, the first clinical trial (phase I / II) was completed in prostate cancer, demonstrating that RV001 has good safety and is well tolerated, and that the drug provides the expected immune response that will exert its effect on the cancer cells. The strong immune response has also been shown to last over time. Therefore, RhoVac® is immediately launching a major Phase IIb clinical trial that will include at least 175 prostate cancer patients. The study, which is expected to be completed in 2021, is designed to show, with statistical significance, the effect of RV001 in preventing disease progression in prostate cancer after surgery or radiation to the primary tumor. RhoVac® is listed on Spotlight, Sweden, a Multilateral Trading Facility (MTF) since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com


Documents & Links